|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
| Brand Name: | |
| Generic Name: | |
| Code Name: | SNS01-T |
| Company: | Senesco |
| FDA Clinical Phase: | 1/2 |
Description:
SNS01-T is a small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA. The Factor 5A gene has been shown to regulate the expression of genes required for programmed cell death. SNS01-T is currently being developed for treatment of multiple myeloma for its potential to …
Results of a recent study show that multiple myeloma patients who were initially treated with either thalidomide or Revlimid demonstrated strong responses to treatment with Revlimid and pomalidomide following relapse. In particular, researchers observed the highest response rates in patients who received treatment with pomalidomide.
Dr. Sumit Madan of Mayo Clinic in Rochester, Minnesota, presented the study results at the American Society of Hematology annual meeting in Orlando last month.
Research has previously shown that thalidomide (Thalomid) and …
Celgene Seeks Expanded Approval For Revlimid In Europe – The pharmaceutical company Celgene announced on Tuesday that it is seeking expanded approval for Revlimid (lenalidomide) as treatment for multiple myeloma in Europe. The European Medicines Agency (EMA) will review approval of Revlimid for maintenance therapy of newly diagnosed myeloma patients who have not progressed after initial therapy with melphalan (Alkeran), prednisone, and Revlimid or after autologous stem cell transplantation. Currently, Revlimid is approved in combination with dexamethasone for the …
A recent study showed that Velcade maintenance therapy modestly increased and deepened responses in elderly, newly diagnosed multiple myeloma patients after Velcade-based induction therapy. Maintenance therapy also caused small increases in the frequency of side effects.
Dr. Ruben Niesvizky of Weill Cornell Medical College in New York presented the study results at the American Society of Hematology (ASH) annual meeting in Orlando at the beginning of the month.
Prior to the recent development of novel therapeutic agents, the treatment for …
Patients under age 65 who undergo autologous stem cell transplantation early have significantly higher survival rates than patients who receive continued treatment with Revlimid and dexamethasone, according to a retrospective analysis of a recent clinical trial.
However, Dr. David Siegel, from the Hackensack University Medical Center in New Jersey and lead investigator of the study, pointed out that these results need to be interpreted cautiously, because the patients were not randomly selected to receive either an early or late stem …
The use of subcutaneous injections to deliver Velcade treatment is comparable in activity, but associated with fewer side effects, than the standard delivery of IV injections in multiple myeloma patients.
“We have similar efficacy with subcutaneous [injections] and a more convenient route of administration for patients, especially those with poor venous access. We don’t require IV central lines, and we do have, most importantly, a reduction in toxicities, which, in my opinion, is really important for our patients,” said Dr. …
Interim results of a Phase 3 trial show no statistically significant differences in relapse and overall survival rates between multiple myeloma patients who received a donor stem cell transplant as their second transplant compared to patients receiving two sequential transplants with their own stem cells.
Patients who received a donor transplant had an increased risk of death and other serious side effects, which outweighed the therapeutic benefits of the procedure.
The results of the trial were presented yesterday by Dr. Amrita Krishnan from the City …
